A DRUG BEING INVESTIGATED RIGHT NOW COULD PROVE TO BE A BIG BREAKTHROUGH FOR MEN WITH LATE STAGE PROSTATE CANCER.
THAT'S ESPECIALLY TRUE IN CASES WHERE THE DISEASE HAS SPREAD TO THE BONE.
GINO POLIDORI SPENT A LOT OF TIME RESTORING THIS CLASSIC ARMY JEEP. IT'S A REMINDER OF A LIFE SPENT SERVING IN THE MILITARY AND AS A LAWMAKER. (pouring coffee)
BUT THIS FAMILY MAN'S MOST IMPORTANT CONTRIBUTION MAY BE WHAT HE'S DOING RIGHT NOW, TESTING A NEW DRUG FOR HIS DISEASE, ADVANCED PROSTATE CANCER.
"I feel it's genetic, and it's gonna follow in the family tree. Here's an opportunity for them to find something to help somebody else down the road."
THE EXPERIMENTAL DRUG, CABOZANTINIB WORKS BY TARGETING TWO PROTEINS LINKED TO THE GROWTH AND SPREAD OF PROSTATE CANCER.
IN A TRIAL OF 171 MEN WITH METASTATIC PROSTATE CANCER, 74-PERCENT HAD THEIR TUMORS SHRINK.
67-PERCENT OF PATIENTS WITH PAIN REPORTED LESS PAIN. AND TAKE A LOOK AT THESE SCANS THE BLACK AREAS MARK WHERE CANCER SPREAD TO THE BONE. IN 82 PATIENTS, BONE METASTASES WERE PARTIALLY OR COMPLETELY RESOLVED. DOCTOR MAHA HUSSAIN CO-AUTHORED THE DRUG STUDY.
SHE SAYS ITS ANTI-CANCER EFFECTS ARE VERY PROMISING.
"It does appear to slow the cancer from growing, but it does not cure the cancer, obviously. The early signs that we have seen have been encouraging and dramatic."
FOR GINO, IT'S AN OPPORTUNITY TO SLOW HIS CANCER AND RELIEVE HIS PAIN.
HE HOPES SOMEDAY NO ONE WILL HAVE TO EXPERIENCE WHAT HE'S LIVING THROUGH.
RIGHT NOW RESEARCHERS ARE CONTINUING TO EVALUATE THE DRUG NOT ONLY FOR PROSTATE CANCER, BUT FOR PATIENTS WITH OTHER CANCERS INCLUDING OVARIAN AND BREAST CANCERS THAT HAVE SPREAD TO THE BONE.
A recall for epipen devices has expanded in the US and…
Dentistry from the Heart gets underway at 7:30 Friday morning.
Banner Health in Phoenix is starting the first phase of a clinical…